{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:19:38Z","timestamp":1787732378837,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Linkou Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bj.2026.101019","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:10:28Z","timestamp":1785251428000},"page":"101019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Imipramine Reverses Sorafenib Resistance in Hepatocellular Carcinoma by Targeting the BLOC1S5\/FOXO1 Signaling Axis"],"prefix":"10.1016","author":[{"given":"Yang-Hsiang","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jung","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5649-2222","authenticated-orcid":false,"given":"Kwang-Huei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bj.2026.101019_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.bj.2026.101019_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32579","article-title":"Antidepressant Use and Mortality Among Patients With Hepatocellular Carcinoma","volume":"6","author":"Huang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10128","key":"10.1016\/j.bj.2026.101019_bib3","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bj.2026.101019_bib4","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.21873\/anticanres.16266","article-title":"Anticancer Effects of Antidepressants in Hepatocellular Carcinoma Cells","volume":"43","author":"Huang","year":"2023","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.bj.2026.101019_bib5","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.21873\/anticanres.17360","article-title":"Imipramine-mediated Suppression of EGFR Signaling Attenuates Invasive and Progressive Abilities of Hepatocellular Carcinoma Cells","volume":"44","author":"Fu","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bj.2026.101019_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430028","article-title":"Updates on Systemic Therapy for Hepatocellular Carcinoma","volume":"44","author":"Ntellas","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.bj.2026.101019_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117118","article-title":"Research progress of sorafenib drug delivery system in the treatment of hepatocellular carcinoma: An update","volume":"177","author":"Fan","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.bj.2026.101019_bib8","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.7150\/ijbs.107195","article-title":"Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies","volume":"21","author":"Chen","year":"2025","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10.1016\/j.bj.2026.101019_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.devcel.2015.04.008","article-title":"BORC and BLOC-1: Shared subunits in trafficking complexes","volume":"33","author":"Langemeyer","year":"2015","journal-title":"Dev Cell"},{"issue":"10","key":"10.1016\/j.bj.2026.101019_bib10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41436-020-0867-5","article-title":"BLOC1S5 pathogenic variants cause a new type of Hermansky-Pudlak syndrome","volume":"22","author":"Pennamen","year":"2020","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.bj.2026.101019_bib11","first-page":"2701","article-title":"IRF4-BLOC1S5: the first rearrangement gene identified in TEMPI syndrome","volume":"109","author":"Zhao","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bj.2026.101019_bib12","first-page":"1","article-title":"Stability of HBV DNA in cell lines and nude mouse-passaged tissues derived from human hepatocellular carcinoma","volume":"27","author":"Chen","year":"1994","journal-title":"Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.bj.2026.101019_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102250","article-title":"ANGPTL3 overcomes sorafenib resistance via suppression of SNAI1 and CPT1A in liver cancer","volume":"52","author":"Lin","year":"2025","journal-title":"Transl Oncol"},{"issue":"6","key":"10.1016\/j.bj.2026.101019_bib14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jhep.2014.12.035","article-title":"Repression of microRNA-130b by thyroid hormone enhances cell motility","volume":"62","author":"Lin","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.bj.2026.101019_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.bj.2026.101019_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010090","article-title":"Role of FoxO Proteins in Cellular Response to Antitumor Agents","volume":"11","author":"Beretta","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bj.2026.101019_bib17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s41065-025-00564-8","article-title":"Cancer cell plasticity and therapeutic resistance: mechanisms, crosstalk, and translational perspectives","volume":"162","author":"Ghorbian","year":"2025","journal-title":"Hereditas"},{"issue":"6","key":"10.1016\/j.bj.2026.101019_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-Based Nanoparticles for Drug\/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater Au"},{"key":"10.1016\/j.bj.2026.101019_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215717","article-title":"The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events","volume":"540","author":"Timilsina","year":"2022","journal-title":"Cancer Lett."},{"issue":"19","key":"10.1016\/j.bj.2026.101019_bib20","doi-asserted-by":"crossref","first-page":"9350","DOI":"10.1111\/jcmm.16874","article-title":"Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide","volume":"25","author":"Wang","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bj.2026.101019_bib21","article-title":"Role of Forkhead Box O Proteins in Hepatocellular Carcinoma Biology and Progression","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bj.2026.101019_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12935-023-03090-7","article-title":"Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics","volume":"23","author":"Tabnak","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bj.2026.101019_bib23","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2024.1163","article-title":"MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation","author":"Wang","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.bj.2026.101019_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112873","article-title":"CircGNAO1 suppresses hepatocellular carcinoma progression and metastasis via sponging miR-182-5p and regulating FOXO1 expression","volume":"140","author":"Ju","year":"2024","journal-title":"Int Immunopharmacol"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:54Z","timestamp":1787729634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417026000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"alternative-id":["S2319417026000752"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2026.101019","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imipramine Reverses Sorafenib Resistance in Hepatocellular Carcinoma by Targeting the BLOC1S5\/FOXO1 Signaling Axis","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2026.101019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"101019"}}